Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib for Neoadjuvant Treatment of Locally Advanced or Unresectable PPGL
NCT05883085Phase 2Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- May 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib in pheochromocytoma and Paraganglioma (PGL), sponsored by Peking Union Medical College Hospital. Primary endpoint: Proportion of patients whose PPGL change from unresectable to resectable tumor at Cycle 4. Status: unknown.
02
Drugs
anlotinib
03
Conditions
pheochromocytomaParaganglioma (PGL)
Beyond the preview
Go deeper on NCT05883085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05883085.